Is Dermata Therapeutics Stock a Good Investment?

Dermata Therapeutics Investment Advice

  DRMAW
To provide specific investment advice or recommendations on Dermata Therapeutics Warrant stock, we recommend investors consider the following general factors when evaluating Dermata Therapeutics Warrant. This will help you to make an informed decision on whether to include Dermata Therapeutics in one of your diversified portfolios:
  • Examine Dermata Therapeutics' financial health by looking at its balance sheet, income statement, and cash flow statement. Analyze key financial ratios, such as Price-to-Earnings (P/E), Price-to-Sales (P/S), and Price-to-Book (P/B), to determine whether the stock is fairly valued or over/undervalued.
  • Research Dermata Therapeutics' leadership team and their track record. Good management can help Dermata Therapeutics navigate difficult times and make strategic decisions that benefit shareholders and increases its net worth.
  • Consider the overall health of the Biotechnology space and any emerging trends that could impact Dermata Therapeutics' business and its evolving consumer preferences.
  • Compare Dermata Therapeutics' performance and market position to its competitors. Analyze how Dermata Therapeutics is positioned in terms of product offerings, innovation, and market share.
  • Check if Dermata Therapeutics pays a dividend and its dividend yield and payout ratio.
  • Review what financial analysts are saying about Dermata Therapeutics' stock and their price targets. However, remember that analysts' opinions can vary, and their predictions may not always be accurate.
It's important to note that investing in Dermata Therapeutics Warrant stock, carries risks, and you should carefully consider your investment goals and risk tolerance before making any investment decisions. Also, remember that it's important for investors to have a long-term perspective and a well-diversified portfolio to manage the impact of stock market volatility on their investments. Below is a detailed guide on how to decide if Dermata Therapeutics Warrant is a good investment.
 
Sell
 
Buy
Sell
We provide trade advice to complement the prevailing expert consensus on Dermata Therapeutics. Our dynamic recommendation engine uses a multidimensional algorithm to analyze the company's potential to grow using all technical and fundamental data available at the time. Use Dermata Therapeutics book value per share and total asset to ensure your buy or sell decision on Dermata Therapeutics is adequate. As Dermata Therapeutics appears to be a penny stock we also advise to verify its cash flow from operations numbers.

Market Performance

SolidDetails

Volatility

Out of controlDetails

Hype Condition

Over hypedDetails

Current Valuation

OvervaluedDetails

Odds Of Distress

Quite HighDetails

Economic Sensitivity

Follows the market closelyDetails

Investor Sentiment

ImpartialDetails

Analyst Consensus

Not AvailableDetails

Financial Strenth (F Score)

FrailDetails

Financial Leverage

InapplicableDetails

Reporting Quality (M-Score)

Unlikely ManipulatorDetails

Examine Dermata Therapeutics Stock

Researching Dermata Therapeutics' stock involves analyzing various aspects of the company and its industry to make an informed investment decision. The key areas to focus on are fundamentals, business model and competitive advantage. It is also important to analyze trends in revenue, net income, and cash flow, as well as key financial ratios, such as price-to-earnings (P/E), price-to-sales (P/S), and debt-to-equity (D/E). The company recorded a loss per share of 2.16. Dermata Therapeutics had not issued any dividends in recent years.
To determine if Dermata Therapeutics is a good investment, evaluating the company's potential for future growth is also very important. This may include expanding into new markets, launching new products or services, or improving operational efficiency. Companies with strong growth prospects can be more attractive investments. This aspect of the research should be conducted in the context of the overall market and industry in which the company operates and should include an analysis of growth potential, competitive landscape, and any regulatory or economic factors that could impact the business. Some of the essential points regarding Dermata Therapeutics' research are outlined below:
Dermata Therapeutics is way too risky over 90 days horizon
Dermata Therapeutics has some characteristics of a very speculative penny stock
Dermata Therapeutics appears to be risky and price may revert if volatility continues
Dermata Therapeutics has high likelihood to experience some financial distress in the next 2 years
Net Loss for the year was (7.79 M) with profit before overhead, payroll, taxes, and interest of 0.
Dermata Therapeutics generates negative cash flow from operations
Dermata Therapeutics has a frail financial position based on the latest SEC disclosures

Dermata Therapeutics Quarterly Liabilities And Stockholders Equity

6.69 Million

100%

Dermata Therapeutics' profitablity analysis

Last ReportedProjected for Next Year
Return On Tangible Assets(0.88)(0.92)
Return On Capital Employed(1.14)(1.20)
Return On Assets(0.88)(0.92)
Return On Equity(1.41)(1.48)
Determining Dermata Therapeutics' profitability involves analyzing its financial statements and using various financial metrics to determine if Dermata Therapeutics is a good buy. For example, gross profit margin measures Dermata Therapeutics' profitability after accounting for the cost of goods sold, while net profit margin measures profitability after accounting for all expenses. Other important metrics include return on assets, return on equity, and free cash flow. By reviewing multiple sources and metrics, you can gain a complete picture of Dermata Therapeutics' profitability and make more informed investment decisions.
Please note, the imprecision that can be found in Dermata Therapeutics' accounting process means that the reasonable investor should take a skeptical approach toward the financial statement analysis of Dermata Therapeutics Warrant. Check Dermata Therapeutics' Beneish M Score to see the likelihood of Dermata Therapeutics' management manipulating its earnings.

Evaluate Dermata Therapeutics' management efficiency

The company has return on total asset (ROA) of (1.0289) % which means that it has lost $1.0289 on every $100 spent on assets. This is way below average. Similarly, it shows a return on equity (ROE) of (2.022) %, meaning that it generated substantial loss on money invested by shareholders. Dermata Therapeutics' management efficiency ratios could be used to measure how well Dermata Therapeutics manages its routine affairs as well as how well it operates its assets and liabilities. Return On Tangible Assets is likely to drop to -0.92 in 2025. Return On Capital Employed is likely to drop to -1.2 in 2025. Debt To Assets is likely to climb to 5.53 in 2025, whereas Total Assets are likely to drop slightly above 6.4 M in 2025.
Last ReportedProjected for Next Year
Book Value Per Share 29.48  30.96 
Tangible Book Value Per Share 29.48  30.96 
Enterprise Value Over EBITDA(20.62)(21.65)
Price Book Value Ratio 0.25  0.26 
Enterprise Value Multiple(20.62)(21.65)
Price Fair Value 0.25  0.26 
Enterprise Value70.8 M67.2 M
Evaluating the management effectiveness of Dermata Therapeutics allows investors to assess its financial health and operational efficiency. Coupled with an analysis of its growth prospects and the current market dynamics, we evaluate the stock's true value and future potential. Key indicators such as revenue, earnings or debt levels are examined alongside external factors like economic trends and regulatory changes. The Dermata Stock analysis seeks to determine whether the stock is undervalued, appropriately priced, or overvalued, thereby guiding your investment decisions.
Beta
0.668

Basic technical analysis of Dermata Stock

As of the 22nd of February, Dermata Therapeutics shows the Coefficient Of Variation of 663.0, mean deviation of 11.86, and Downside Deviation of 18.02. Dermata Therapeutics technical analysis allows you to utilize historical prices and volume patterns in order to determine a pattern that computes the direction of the firm's future prices. Please confirm Dermata Therapeutics standard deviation, maximum drawdown, as well as the relationship between the Maximum Drawdown and expected short fall to decide if Dermata Therapeutics is priced favorably, providing market reflects its regular price of 0.03 per share. As Dermata Therapeutics appears to be a penny stock we also advise to verify its total risk alpha numbers.

Dermata Therapeutics' insider trading activities

Some recent studies suggest that insider trading raises the cost of capital for securities issuers and decreases overall economic growth. Trading by specific Dermata Therapeutics insiders, such as employees or executives, is commonly permitted as long as it does not rely on Dermata Therapeutics' material information that is not in the public domain. Local jurisdictions usually require such trading to be reported in order to monitor insider transactions. In many U.S. states, trading conducted by corporate officers, key employees, directors, or significant shareholders must be reported to the regulator or publicly disclosed, usually within a few business days of the trade. In these cases Dermata Therapeutics insiders are required to file a Form 4 with the U.S. Securities and Exchange Commission (SEC) when buying or selling shares of their own companies.

Understand Dermata Therapeutics' technical and predictive indicators

Using predictive indicators to make investment decisions involves analyzing Dermata Therapeutics' various financial and market-based factors to help forecast future trends and identify investment opportunities. Select the indicators that are most relevant to your investment strategy. Each indicator has its own strengths and weaknesses, so it's essential to combine multiple indicators to get a more comprehensive view of the market and reduce the risk of making poor decisions based on limited data.

Consider Dermata Therapeutics' intraday indicators

Dermata Therapeutics intraday indicators are useful technical analysis tools used by many experienced traders. Just like the conventional technical analysis, daily indicators help intraday investors to analyze the price movement with the timing of Dermata Therapeutics stock daily movement. By combining multiple daily indicators into a single trading strategy, you can limit your risk while still earning strong returns on your managed positions.
Dermata Therapeutics time-series forecasting models is one of many Dermata Therapeutics' stock analysis techniques aimed to predict future share value based on previously observed values. Time-series forecasting models ae widely used for non-stationary data. Non-stationary data are called the data whose statistical properties e.g. the mean and standard deviation are not constant over time but instead, these metrics vary over time. These non-stationary Dermata Therapeutics' historical data is usually called time-series. Some empirical experimentation suggests that the statistical forecasting models outperform the models based exclusively on fundamental analysis to predict the direction of the market movement and maximize returns from investment trading.

Dermata Stock media impact

Far too much social signal, news, headlines, and media speculation about Dermata Therapeutics that are available to investors today. That information is available publicly through Dermata media outlets and privately through word of mouth or via Dermata internal channels. However, regardless of the origin, that massive amount of Dermata data is challenging to quantify into actionable patterns, especially for investors that are not very sophisticated with ever-evolving tools and techniques used in the investment management field.
A primary focus of Dermata Therapeutics news analysis is to determine if its current price reflects all relevant headlines and social signals impacting the current market conditions. A news analyst typically looks at the history of Dermata Therapeutics relative headlines and hype rather than examining external drivers such as technical or fundamental data. It is believed that price action tends to repeat itself due to investors' collective, patterned thinking related to Dermata Therapeutics' headlines and news coverage data. This data is often completely overlooked or insufficiently analyzed for actionable insights to drive Dermata Therapeutics alpha.

Dermata Therapeutics Corporate Management

Mr MPHVP DevelProfile
Maria MBASenior AssuranceProfile
Gerald ProehlChairman, CoFounderProfile
Kyri HooseVP CFOProfile
Sean ProehlSenior DevelopmentProfile
Dr MPHSenior OfficerProfile

Additional Tools for Dermata Stock Analysis

When running Dermata Therapeutics' price analysis, check to measure Dermata Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Dermata Therapeutics is operating at the current time. Most of Dermata Therapeutics' value examination focuses on studying past and present price action to predict the probability of Dermata Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Dermata Therapeutics' price. Additionally, you may evaluate how the addition of Dermata Therapeutics to your portfolios can decrease your overall portfolio volatility.